EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Point‐of‐care β‐hydroxybutyrate measurement predicts adequate glucose metabolism suppression in cardiac FDG‐PET/CT

Suvi Hartikainen, Tuomo Tompuri, Tiina Laitinen, Tomi Laitinen

Clinical Physiology and Functional Imaging · 2024

DOI: 10.1111/cpf.12881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Physiology and Functional Imaging, 2024. Verfasst von Suvi Hartikainen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, 3-Hydroxybutyric Acid, Fluorodeoxyglucose F18, Predictive Value of Tests. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kuopion Yliopistollinen Sairaala, Sydäntutkimussäätiö, Suomen Lääketieteen Säätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aims of our study were to evaluate whether point‐of‐care β‐hydroxybutyrate (BHB) measurement can be used to identify patients with adequate cardiac glucose metabolism suppression for cardiac [ 18 F]‐fluoro‐2‐deoxy‐ d ‐glucose‐positron emission tomography with computerized tomography (FDG‐PET/CT) and to develop a pretest probability calculator of myocardial suppression using other metabolic factors attainable before imaging. Methods and Results We recruited 193 patients with any clinical indication for whole body [ 18 F]‐FDG‐PET/CT. BHB level was measured with a point‐of‐care device. Maximal myocardial standardized uptake value using lean body mass (SULmax) was measured from eight circular regions of interest with 1 cm circumference and background from left ventricular blood pool. Correlations SULmax and point‐of‐care measured BHB were analysed. The ability of BHB test to predict adequate suppression was evaluated with receiver operating characteristic analysis. Liver and spleen attenuation in computed tomography were measured to assess the presence of fatty liver. BHB level correlated with myocardial uptake and, using a cut‐off value of 0.35 mmol/L to predict adequate myocardial suppression, we reached specificity of 90% and sensitivity of 56%. Other variables to predict adequate suppression were diabetes, obesity, ketogenic diet and fatty liver. Using information attainable before imaging, we created a pretest probability calculator of inadequate myocardial glucose metabolism suppression. The area under the curve for BHB test alone was 0.802 and was 0.857 for the pretest calculator ( p = 0.319).

Conclusions

BHB level measured with a point‐of‐care device is useful in predicting adequate myocardial glucose metabolism suppression. More detailed assessment of other factors potentially contributing to cardiac metabolism is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed Tomography3-Hydroxybutyric AcidFluorodeoxyglucose F18Predictive Value of TestsRadiopharmaceuticalsMyocardiumBiomarkersHumansMaleFemaleMiddle AgedAgedPoint-of-Care TestingGlucoseReproducibility of ResultsROC CurveArea Under Curve

Stichwörter der Autor:innen

BHBglucose metabolismmyocardial inflammationmyocardiumβ‐hydroxybutyrate

Substanzen

3-Hydroxybutyric AcidFluorodeoxyglucose F18RadiopharmaceuticalsBiomarkersGlucose

Autor:innen und Institutionen

  • Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Department of Clinical Physiology, North Karelia Central Hospital, Joensuu, Finland.

Förderung

  • Kuopion Yliopistollinen Sairaala
  • Sydäntutkimussäätiö
  • Suomen Lääketieteen Säätiö

Zitieren

APA

Hartikainen, S., Tompuri, T., Laitinen, T., & Laitinen, T. (2024). Point‐of‐care β‐hydroxybutyrate measurement predicts adequate glucose metabolism suppression in cardiac FDG‐PET/CT. Clinical Physiology and Functional Imaging. https://doi.org/10.1111/cpf.12881

Vancouver

Hartikainen S, Tompuri T, Laitinen T, Laitinen T. Point‐of‐care β‐hydroxybutyrate measurement predicts adequate glucose metabolism suppression in cardiac FDG‐PET/CT. Clinical Physiology and Functional Imaging. 2024. doi:10.1111/cpf.12881

BibTeX
@article{Hartikainen2024,
  author = {Hartikainen, Suvi and Tompuri, Tuomo and Laitinen, Tiina and Laitinen, Tomi},
  title = {Point‐of‐care β‐hydroxybutyrate measurement predicts adequate glucose metabolism suppression in cardiac FDG‐PET/CT},
  journal = {Clinical Physiology and Functional Imaging},
  year = {2024},
  doi = {10.1111/cpf.12881}
}
Kostenlos starten →